UPC APP 34350/2025
EP3854403 Einheitspatent · USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Division
- Milan CD
- Richter
- —
- Technologie
- ChemistryPharmaceuticals
- Sprache
- —
- Erste Entscheidung
- 4. Sept. 2025
- EPA-Einspruch
- Gilead Sciences, Inc.Zulässig2025-06-18
| Median Tage bis zur ersten Entscheidung | |
|---|---|
| Gesamt-UPC | 124 |
| Milan CD | Gesperrt |
Vor dem UPC: Gilead Sciences, Inc. (5 Verfahren)·Academy of Military Medical Sciences (5 Verfahren)
Dieser Streit umfasst 4 weitere Verfahren
UPC CoA 121/2026·UPC CoA 103/2026·UPC CFI 1968/2026·UPC CFI 552/2025
Starten Sie die kostenlose Testphase, um die Ausgänge zu sehen.
- 2025-09-04
Zusammenfassung: Milan Central Division judge-rapporteur issued a procedural order in the revocation action by Gilead Sciences against Academy of Military Medical Sciences (patent EP 3 854 403, Remdesivir for MERS/SARS-CoV-1). The order resolved disputes on the validity of service on the Chinese defendant via its EPO patent representative Lavoix. The court held that service on the patent representative within the CMS was valid under Rule 271(6) RoP. Lavoix's objections to service were inadmissible as the patent representative had no standing to defend the patent holder without a power of attorney. Gilead's premature request for a default judgment was declared currently inadmissible.
Rechtsfragen anzeigen (4)
- Service of proceedings on foreign defendant via EPO patent representative under Rule 271 RoP
- Standing of patent representative to raise procedural objections
- Default judgment admissibility under Rule 355/356 RoP
- Validity of service within vs outside CMS
- EAA9DAF11A1C547DBE32D677B84E5F16_en.pdf2025-09-04EN